Core Viewpoint - AnuoYuda Gene Technology (Beijing) Co., Ltd. has submitted its application for listing on the Hong Kong Stock Exchange, with CCB International and Guotai Junan International as joint sponsors. The company previously submitted its listing application on March 25 [1]. Company Overview - AnuoYuda specializes in molecular diagnostics-based IVD medical devices and multi-omics life science research services, focusing on NGS-based prenatal testing IVD products. Its clinical sequencing solutions include self-produced IVD testing kits, gene sequencers, and bioinformatics analysis software, along with technical support and laboratory design services [3][4]. - The company's clients primarily consist of hospitals certified for prenatal diagnosis and independent medical laboratories (ICLs), which purchase IVD products and pay fees based on the number and type of products purchased [3]. Market Position - AnuoYuda's NIPT testing kit, aimed at detecting the three most common chromosomal disorders (trisomy 21, 18, and 13), received Class III medical device certification in 2017, establishing its market position in prenatal testing. According to ZhiShi Consulting, AnuoYuda ranks second in China's NIPT market by sample testing volume in 2024, with market shares of 11.6%, 12.1%, and 15.5% for 2022, 2023, and 2024, respectively. By revenue, the company ranks third in the NIPT market with a market share of 14.6% [3]. Product Offerings - The company provides two types of life science sequencing solutions: clinical sequencing solutions and research sequencing solutions. In the clinical sequencing solutions line, AnuoYuda procures reagents and equipment components from upstream suppliers and sells IVD testing kits, proprietary gene sequencers, and bioinformatics software to hospitals and independent medical laboratories [4]. - In the research sequencing solutions line, the company sources gene sequencers, testing kits, and other equipment from upstream suppliers to offer six types of research sequencing solutions to academic institutions, research organizations, and corporate clients, primarily for multi-omics research in agriculture, forestry, animal husbandry, and fisheries [4]. Production Capacity - As of September 23, 2025, AnuoYuda operates three production facilities in China, primarily producing testing kits and sequencers. During the reporting period, the combined annual production capacity of the facilities is 40 NextSeq550AR sequencers and 48,000 testing kits [4]. Financial Performance - The company's revenue from continuing operations for the six months ended June 30 for the years 2022, 2023, 2024, and 2025 was approximately RMB 435.1 million, RMB 475.0 million, RMB 518.1 million, and RMB 269.3 million, respectively. The annual losses for the same periods were approximately RMB 67 million, RMB 240 million, RMB 126 million, and RMB 29 million [6][7].
安诺优达再度递表港交所 报告期内累计亏损超4.6亿元
Zhi Tong Cai Jing·2025-10-01 02:12